Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia-Reference-Cited by-同舟云学术

Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia

Published:2016-03-09 Issue:9 Volume:76 Page:2766-2777
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Dolai Sibasish,Sia Keith C.S.,Robbins Alissa K.,Zhong Ling,Heatley Sue L.,Vincent Tiffaney L.,Hochgräfe Falko,Sutton Rosemary,Kurmasheva Raushan T.,Revesz Tamas,White Deborah L.,Houghton Peter J.,Smith Malcolm A.,Teachey David T.,Daly Roger J.,Raftery Mark J.,Lock Richard B.

Funder

Australian National Health and Medical Research

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vivo activity of the dual SYK/FLT3 inhibitor TAK‐659 against pediatric acute lymphoblastic leukemia xenografts;Pediatric Blood & Cancer;2023-06-20

2. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation;Journal of Clinical Investigation;2021-12-15

3. Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia;Leukemia;2021-04-24

4. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in CRLF2-Rearranged Ph-like ALL;Molecular Cancer Research;2020-08-14

5. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis;Molecular Cancer Therapeutics;2020-08-04